No Data
Chordia Therapeutics Regains Rights to CTX-177 as Ono Discontinues Development
Chordia Therapeutics
＜190A＞Chordia Therapeutics Inc. Mitsubishi UFJ Capital Co., Ltd. (Partnership Name) Mitsubishi UFJ Life Sciences No. 1 Investment Limited Partnership Shareholding ratio 5.89% → 4.85% Reporting obligation date 2025/04/18
Express News | [Change Report] Mitsubishi UFJ reports a decrease in its shareholding in Chordia Therapeutics (190A.JP) to 4.85%.
Chordia---In the second quarter, research and development of the pipeline, centered around rogocekib, is progressing smoothly.
Chordia Therapeutics <190A> announced its financial results for the second quarter of the fiscal year ending August 2025 (September 2024 - February 2025) on the 11th. Business revenue was not applicable (the same period last year was not applicable), with an operating loss of 0.996 billion yen (compared to a loss of 0.809 billion yen), an ordinary loss of 0.975 billion yen (compared to a loss of 0.801 billion yen), and a net loss of 0.976 billion yen (compared to a loss of 0.802 billion yen). During this interim accounting period, the CLK inhibitor CTX-712, international nonproprietary name is
Chordia Therapeutics: Interim financial results presentation materials for the fiscal year ending 2025/8
Chordia Therapeutics Reports Financial Losses for Six-Month Period Ending February 2025
